Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Fellenberg, Jörg ^a   Kunz, Pierre ^a   Sähr, Heiner ^a   Depeweg, Daniela ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CASPASE 9; CISPLATIN; INOSINATE DEHYDROGENASE; INOSINE 5' MONOPHOSPHATE DEHYDROGENASE TYPE II; METHOTREXATE; MYCOPHENOLIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; APOPTOSIS REGULATORY PROTEIN; IMPDH2 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; ENZYME INACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; OSTEOSARCOMA CELL; PROTEIN CLEAVAGE; RNA INTERFERENCE; WESTERN BLOTTING; WILD TYPE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMP DEHYDROGENASE; INHIBITORY CONCENTRATION 50; METHOTREXATE; MYCOPHENOLIC ACID; OSTEOSARCOMA;

EID: 77957859532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012179     Document Type: Article

References (32)

1. Uribe-Botero G, Russell WO, Sutow WW, Martin RG (1977) Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 67: 427-435.
2. Meyers PA, Heller G, Healey J, Huvos A, Lane J, et al. (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10: 5-15.
3. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84.
4. Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, et al. (1991) Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 9: 600-605.
5. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, et al. (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568.
6. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A (2007) Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol 20: 1085-1094.
7. Knight RD, Mangum J, Lucas DL, Cooney DA, Khan EC, et al. (1987) Inosine monophosphate dehydrogenase and myeloid cell maturation. Blood 69: 634-639.
8. Itoh O, Kuroiwa S, Atsumi S, Umezawa K, Takeuchi T, et al. (1989) Induction by the guanosine analogue oxanosine of reversion toward the normal phenotype of K-ras-transformed rat kidney cells. Cancer Res 49: 996-1000.
9. Jackson RC, Weber G, Morris HP (1975) IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256: 331-333.
10. Zimmermann A, Gu JJ, Spychala J, Mitchell BS (1996) Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Adv Enzyme Regul 36: 75-84.
11. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, et al. (1991) Selective up-regulation of type II inosine 59-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 51: 3886-3890.
12. Natsumeda Y, Carr SF (1993) Human type I and II IMP dehydrogenases as drug targets. Ann N Y Acad Sci 696: 88-93.
13. Franchetti P, Cappellacci L, Grifantini M (1996) IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Farmaco 51: 457-469.
14. Ratcliffe AJ (2006) Inosine 59-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases. Curr Opin Drug Discov Devel 9: 595-605.
15. Chen L, Pankiewicz KW (2007) Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 10: 403-412.
16. Sidi Y, Panet C, Wasserman L, Cyjon A, Novogrodsky A, et al. (1988) Growth inhibition and induction of phenotypic alterations in MCF-7 breast cancer cells by an IMP dehydrogenase inhibitor. Br J Cancer 58: 61-63.
17. Olah E, Natsumeda Y, Ikegami T, Kote Z, Horanyi M, et al. (1988) Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells. Proc Natl Acad Sci U SA 85: 6533-6537.
18. Jayaram HN, Cooney DA, Grusch M, Krupitza G (1999) Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem 6: 561-574.
19. Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, et al. (1996) Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res 16: 3349-3351.
20. Penuelas S, Noe V, Ciudad CJ (2005) Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J 272: 696-710.
21. Penuelas S, Noe V, Morales R, Ciudad CJ (2005) Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit 11: BR6-BR12.
22. Fellenberg J, Dechant MJ, Ewerbeck V, Mau H (2003) Identification of drugregulated genes in osteosarcoma cells. Int J Cancer 105: 636-643.
23. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, et al. (2006) IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 5: 457-466.
24. Nagai M, Natsumeda Y, Weber G (1992) Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 52: 258-261.
25. Gharehbaghi K, Burgess GS, Collart FR, Litz-Jackson S, Huberman E, et al. (1994) p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Leukemia 8: 1257-1263.
26. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, et al. (2005) Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 24: 5888-5896.
27. Khanna N, Jayaram HN, Singh N (2004) Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci 75: 179-190.
28. Yalowitz JA, Jayaram HN (2000) Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res 20: 2329-2338.
29. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, et al. (1989) Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 59-phosphate dehydrogenase activity. Cancer Res 49: 3696-3701.
30. Sun XX, Dai MS, Lu H (2008) Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 283: 12387-12392.
31. Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, et al. (2004) Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer 108: 812-817.
32. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM (1996) A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10: 934-947.